Buy & Sell Exxon Mobil Corporation (XOM) – Exxon Mobil Corporation Price Today
Aura AI Summary
Key Stats
- $621.41BMarket Cap
- EnergySector
- -15.82%3M Drawdown
- $660.64BEnterprise Value
- 2.75%Dividend Yield
- 92 daysTypical Hold Time
Exxon Mobil Corporation (XOM) is currently valued at a market capitalization of $621.41B, with an enterprise value of $660.64B. Over the past 52 weeks, Exxon Mobil Corporation has traded between a low of $104.27 and a high of $171.52, highlighting its annual price range. Over the past three months, Exxon Mobil Corporation has recorded a drawdown of -15.82%, reflecting recent price volatility. Exxon Mobil Corporation offers a dividend yield of 2.75%, with the most recent dividend of $1.03 paid on 15 May 26. On average, investors hold Exxon Mobil Corporation for approximately 92 days, indicating typical investor behavior on the platform.
About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Most Recent News
Cyabra inks $500K+ deal to fight online hate with AI-powered disinformation detection for global research institute
Cyabra, an AI-driven disinformation intelligence company, has secured a contract worth over $500,000 to provide its technology to a leading international research institute focused on tracking global hate speech. The platform will help identify coord...

Ormat launches Ormega100, the largest binary geothermal unit, to boost Enhanced Geothermal System deployment.
Ormat Technologies introduced the Ormega100, the industry's largest binary power generation unit delivering 100 MW output, designed to accelerate commercialization and scaling of Enhanced Geothermal Systems (EGS). With 60 years of expertise and exten...

ADARx to present Phase 1/2 data on Onvuzosiran for hereditary angioedema at 2026 EAACI Congress
ADARx Pharmaceuticals announced it will present Phase 1/2 clinical data for Onvuzosiran, an RNA therapy for hereditary angioedema (HAE), at the 2026 EAACI Congress in Istanbul. Onvuzosiran targets plasma prekallikrein to prevent swelling attacks by r...
